Date NameAddress Dear Senator/Representative/Governor _____________________: My name is _______________, and I am a __year old man/woman living with ______(type of myositis). I was first diagnosed _______. I writing to you today as a member of the myositis community because there is a national shortage of hydroxychloroquine. On March 19, it was announced that chloroquine and hydroxychloroquine were showing promise in the treatment for COVID 19. I am a member of…
Continue Reading
By The National Institute of Environmental Health Sciences 4/8/2020 Autoimmunity, a condition in which the body’s immune system reacts with components of its own cells, appears to be increasing in the United States, according to scientists at the National Institutes of Health and their collaborators. In a study published April 8 in Arthritis and Rheumatology,…
Continue Reading
On March 29, 2020 the U.S. Department of Health and Human Services issued a statement that they have “accepted 30 million doses of hydroxychloroquine sulfate donated by Sandoz, the Novartis generics and biosimilars division, and one million doses of chloroquine phosphate donated by Bayer Pharmaceuticals, for possible use in treating patients hospitalized with COVID-19 or for…
Continue Reading
On March 19, it was announced that chloroquine and hydroxychloroquine were showing promise in the treatment for COVID 19. However, there are no available data from randomized clinical trials to support efficacy, and taking these medications for COVID 19 is not recommended. A recent New York Times Article has noted that a University of Utah…
Continue Reading
Tom Lloyd, MD PhDAssociate Professor of Neurology and Neuroscience at Johns Hopkins University, Co-Director of the Johns Hopkins Myositis Center In a press conference today, President Trump discussed what the FDA was doing to accelerate approval of treatments for the novel coronavirus, COVID-19. Chloroquine, a drug that has been used since World War II to…
Continue Reading